Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mytrex Health TechnologiesROCO:4431 +2.06%64 Piotroski F-Score is 6 as of Jul. 18, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates ROCO:4431 with a GF Score™ of 64/100 and a GF Value™ of NT$37.17 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 2,969 Industrial Products companies, Mytrex Health Technologies ranks better than 75.35% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Mytrex Health Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Mytrex Health Technologies's Piotroski F-Score or its related term are showing as below:
ROCO:4431'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 5 Max: 6
Current: 6
During the past 13 years, the highest Piotroski F-Score of Mytrex Health Technologies was 6. The lowest was 4. And the median was 5.
Mytrex Health Technologies (ROCO:4431) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Mytrex Health Technologies Piotroski F-Score Related Terms
Mytrex Health Technologies Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mytrex Health Technologies Piotroski F-Score Chart
ROCO:4431 vs GEV, ETN, PH: Piotroski F-Score Comparison
For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mytrex Health Technologies Piotroski F-Score vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Mytrex Health Technologies's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Mytrex Health Technologies's current Net Income (TTM) was -17.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Mytrex Health Technologies's current Cash Flow from Operations (TTM) was 201.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Mytrex Health Technologies's return on assets of this year was -0.01448924. Mytrex Health Technologies's return on assets of last year was -0.06547109.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Mytrex Health Technologies's gearing of this year was 0.05762055. Mytrex Health Technologies's gearing of last year was 0.09394197.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Mytrex Health Technologies's current ratio of this year was 1.58446642. Mytrex Health Technologies's current ratio of last year was 1.70711691.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Mytrex Health Technologies's number of shares in issue this year was 36.536. Mytrex Health Technologies's number of shares in issue last year was 36.536.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Mytrex Health Technologies's gross margin of this year was 0.12473186. Mytrex Health Technologies's gross margin of last year was 0.12597545.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Mytrex Health Technologies's asset turnover of this year was 1.69754853. Mytrex Health Technologies's asset turnover of last year was 1.39779.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
1
+
1
+
1
+
0
+
1
+
0
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Mytrex Health Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Mytrex Health Technologies (ROCO:4431) has a Piotroski F-Score of 6 as of Jul. 18, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Mytrex Health Technologies and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Mytrex Health Technologies' Piotroski F-Score has ranged from 4.00 to 6.00. According to the industry distribution chart, Mytrex Health Technologies ranks #732 out of 2969 companies in the Industrial Products industry, placing it in the top 24.7%.
Is Mytrex Health Technologies' Piotroski F-Score too high?
Mytrex Health Technologies' current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 6.00. The Industrial Products industry median Piotroski F-Score is 5.00. Mytrex Health Technologies' value of 6 is 20% above this industry median. Based on the distribution chart, Mytrex Health Technologies ranks #732 out of 2969 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers. Overall, Mytrex Health Technologies has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mytrex Health Technologies' Piotroski F-Score compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Mytrex Health Technologies ranks #732 out of 2969 companies for Piotroski F-Score. This places Mytrex Health Technologies in the top 25% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Mytrex Health Technologies' value of 6 is 20% above this benchmark. Historically, Mytrex Health Technologies' own Piotroski F-Score has ranged from 4.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Mytrex Health Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for an Industrial Products company?
The median Piotroski F-Score among Industrial Products companies is 5.00, based on 2,969 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mytrex Health Technologies's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Mytrex Health Technologies and its competitors. For the Industrial Products industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mytrex Health Technologies's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mytrex Health Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mytrex Health Technologies (ROCO:4431) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$37.17, compared to a current price of NT$17.35 — trading 53.3% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Industrial Products industry median of 5.00. Mytrex Health Technologies' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Mytrex Health Technologies (ROCO:4431), the current Piotroski F-Score is 6 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mytrex Health Technologies (ROCO:4431) Overvalued in 2026?
Based on GuruFocus' analysis, Mytrex Health Technologies stock appears to be undervalued.
The current stock price of NT$17.35 is trading 53.3% below its estimated GF Value™ of NT$37.17.
GuruFocus considers Mytrex Health Technologies to be Significantly Undervalued.
Key valuation signals for ROCO:4431:
Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
GF Value™: NT$37.17 vs. price of NT$17.35 (53.3% below fair value)
Industry Position: 20% above the Industrial Products median (#732 of 2969)
No single metric tells the full story. See the ROCO:4431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.
64GF Score
Get the complete analysis for ROCO:4431
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4431 has been successfully added to your 
